Received Feb 17, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | PC5Y3 | — |
Administered vaccine reconstituted with sterile water; Administered vaccine reconstituted with sterile water; receveid 2nd dose; This non-serious case was reported by a nurse via call center representative and described the occurrence of inappropriate preparation of medication in a 57-year-old female patient who received Herpes zoster (Shingrix) (batch number PC5Y3, expiry date 30-JAN-2027) for prophylaxis. Previously administered products included Shingrix (received 1st on 09-MAR-2024 with expiry date 2P5E9 and expiry date 18-APR-2026). On 24-JAN-2025, the patient received the 2nd dose of Shingrix. On 24-JAN-2025, an unknown time after receiving Shingrix, the patient experienced inappropriate preparation of medication (Verbatim: Administered vaccine reconstituted with sterile water), inappropriate dose of vaccine administered (Verbatim: Administered vaccine reconstituted with sterile water) and drug dose administration interval too long (Verbatim: receveid 2nd dose). The outcome of the inappropriate preparation of medication, inappropriate dose of vaccine administered and drug dose administration interval too long were unknown. Additional Information: GSK Receipt Date: 24-JAN-2025 The nurse explained that on 24th January 2025 they administered a dose of Shingrix but the powder was diluted with sterile water instead of the adjuvant component provided by the manufacturer which led to inappropriate preparation of medication and inappropriate dose of vaccine administered. the patient received the 2nd dose of Shingrix later than the recommended interval, which led to lengthening of vaccine schedule.